Case-control study of postmenopausal hormone replacement therapy and endometrial cancer

American Journal of Epidemiology

Volumn 164, Issue 8, 2006, Pages 775-786

  Strom, Brian L ^a,b   Schinnar, Rita ^a   Weber, Anita L ^a   Bunin, Greta ^a,b   Berlin, Jesse A ^c   Baumgarten, Mona ^d   DeMichele, Angela ^a,b   Rubin, Stephen C ^a,b   Berlin, Michelle ^e   Troxel, Andrea B ^a,b   Rebbeck, Timothy R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Pharmaceutical Research and Development   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Case control studies; Endometrial neoplasm; Estrogens; Hormone replacement therapy; Progestins

Indexed keywords

ESTROGEN; GESTAGEN;

CANCER; FEMALE; HORMONE; WOMENS HEALTH;

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC DRUG ADMINISTRATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK BENEFIT ANALYSIS; RISK REDUCTION; TELEPHONE; UNITED STATES;

AGED; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; INTERVIEWS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MIDDLE AGED; PHILADELPHIA; POSTMENOPAUSE; PROGESTINS; RISK FACTORS;

NORTH AMERICA; PENNSYLVANIA; PHILADELPHIA; UNITED STATES;

EID: 33749484600     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj316     Document Type: Article

References (46)

1. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39.
2. Freedman MA. Quality of life and menopause: the role of estrogen. J Womens Health 2002;11:703-18.
3. Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist downregulated patients with endometriosis and premenstrual syndrome. Menopause 2002;9:236-41.
4. Vestergaard P, Hermann AP, Stilgren L, et al. Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pressure-a randomised controlled study. Maturitas 2003;46:123-32.
5. Quint BC. Changing patterns in endometrial adenocarcinoma: a study of 291 consecutive cases at a large private hospital, 1960-1973. Am J Obstet Gynecol 1975;122:498-501.
6. Weiss NS, Szekely DR, Austin DF. Increasing incidence of endometrial cancer in the United States. N Engl J Med 1976;294:1259-62.
7. Greenwald P, Caputo TA, Wolfgang PE. Endometrial cancer after menopausal use of estrogens. Obstet Gynecol 1977;50:239-43.
8. Walker AM, Jick H. Cancer of the corpus uteri: increasing incidence in the United States, 1970-75. Am J Epidemiol 1979;110:47-51.
9. Marrett LD, Meigs W, Flannery JT. Trends in the incidence of cancer of the corpus uteri in Connecticut, 1964-79: in relation to consumption of exogenous estrogens. Am J Epidemiol 1982;116:57-67.
10. Lyon JL, Gardner JW. The rising frequency of hysterectomy: its effect on uterine cancer rates. Am J Epidemiol 1977;105:439-43.
11. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-14.
12. Paterson ME, Wade-Evans T, Sturdee DW, et al. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 1980;280:822-4.
13. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996;275:370-5.
14. National Cancer Institute. SEER Program: cancer incidence and mortality in the United States 1973-81. Bethesda, MD: Public Health Service, US Department of Health and Human Services, 1984. (NIH publication no. 85-1837).
15. Walker AM, Jick H. Declining rates of endometrial cancer. Obstet Gynecol 1980;56:733-6.
16. Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 1985;65:441-6.
17. Hemminki E, Kennedy DL, Baum C, et al. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health 1988;78:1479-81.
18. Ross RK, Paganini-Hill A, Roy S, et al. Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: possible implications for public health. Am J Public Health 1988;78:516-19.
19. Persson I, Schrnidt M, Adami HO, et al. Trends in endometrial cancer incidence and mortality in Sweden, 1960-84. Cancer Causes Control 1990;3:201-8.
20. Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG 2000;107:1392-400.
21. Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-61.
22. Whitlock EP, Johnson RE, Vogt TM. Recent patterns of hormone replacement therapy use in a large managed care organization. J Womens Health 1998;7:1017-26.
23. Elinson L, Cohen MM, Elmslie T. Hormone replacement therapy: a survey of Ontario physicians' prescribing practices. CMAJ 1999;161:695-8.
24. Nilsen ST, Pedersen AT, Moen MH, et al. Knowledge, attitudes and management strategies in Scandinavia concerning hormone replacement therapy: a comparison between gynecologists in Denmark, Norway and Sweden. Maturitas 2001;39:83-90.
25. Kaplan B, Aschkenazi-Steinberg S, Yogev Y, et al. Gynecologists' trends and attitudes toward prescribing hormone replacement therapy during menopause. Menopause 2002;9:354-9.
26. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
27. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48.
28. Bunin GR, Baumgarten M, Norman SA, et al. Practical aspects of sharing controls between case-control studies. Pharmacoepidemiol Drug Saf 2005;14:523-30.
29. Strom BL, Schinnar R. An interview strategy was critical for obtaining valid information on the use of hormone replacement therapy. J Clin Epidemiol 2004;57:1210-13.
30. Norman SA, Berlin JA, Weber AL, et al. Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes Control. 2003;14:933-43.
31. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. Principles and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982.
32. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36.
33. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-37.
34. (Erratum in: Am J Epidemiol 1989;130:1066).
35. Trope CG, Alektiar KM, Sabbatini PJ, et al. Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins, 2005:823-72.
36. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
37. Reed SD, Voigt LF, Beresford SA, et al. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004;191:1146-51.
38. Mizunuma H, Honjo H, Aso T, et al. Postmenopausal hormone replacement therapy use and risk of endometrial cancer in Japanese women. Climacteric 2001;4:293-8.
39. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
40. Beral V, Bull D, Reeves G, et al. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
41. Horwitz RI, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978;299:1089-94.
42. Bhagavan BS, Parrnley TH, Rosenshein NB, et al. Comparison of estrogen-induced hyperplasia to endometrial cancer. Obstet Gynecol 1984;64:12-15.
43. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-22.
44. Persson I, Bergkvist L, Adami HO. Reliability of women's histories of climacteric oestrogen treatment assessed by prescription forms. Int J Epidemiol 1987;16:222-8.
45. Goodman MT, Nomura AM, Wilkens LR, et al. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990;131:815-25.
46. Grady D, Ernster VL. Endometrial cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer epidemiology and prevention. 2nd ed. New York, NY: Oxford University Press, 1996:1058-89.